{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:30:03Z","timestamp":1791009003869,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T00:00:00Z","timestamp":1326067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with chronic lymphocytic leukaemia (CLL) whose tumour cells harbour a 17p deletion (17p\u2010) are universally considered to have a poor prognosis. The deletion can be detected at diagnosis or during the evolution of the disease, particularly in patients who have received chemotherapy. We sought to evaluate the natural history of patients with 17p\u2010 CLL, identify predictive factors within this prognostic subgroup, and evaluate the results of different therapeutic approaches. Data from 294 patients with 17p\u2010 CLL followed up at 20 different institutions was retrospectively collected and analysed. Median age was 68 (range 27\u201398) years at the time of fluorescence <jats:italic>in situ<\/jats:italic> hybridization analysis. After 17p\u2010 documentation, 52% received treatment, achieving an overall response rate of 50%. Median overall survival was 41\u2003months, and was significantly shorter in patients with elevated beta<jats:sub>2<\/jats:sub>\u2010microglobulin concentration (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001), B symptoms (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7016), higher percentage of cells with deletion (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001), and acquired deletions (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7012). These findings suggest that patients with 17p\u2010 CLL have a variable prognosis that can be refined using simple clinical and laboratory features, including 17p\u2010 clone size, beta2\u2010microglobulin concentration, presence of B symptoms and type of deletion (<jats:italic>de novo versus<\/jats:italic> acquired).<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.09000.x","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T07:43:42Z","timestamp":1326095022000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results"],"prefix":"10.1111","volume":"157","author":[{"given":"Julio","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Espinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de la Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Hernandez\u2010Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Ferra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aventin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Puiggros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Abella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Grupo Espa\u00f1ol de Leucemia Linfatica Cronica (GELLC) y Grupo Espa\u00f1ol de Citogenetica Hematologica (GECGH)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.260"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07699.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"P53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B\u2010Cell leukemias","volume":"85","author":"Dohner H.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404441"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275420"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0838"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3089"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20794"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3729"},{"key":"e_1_2_7_16_1","first-page":"180","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"M\u00fcller\u2010Hermelink H.K.","year":"2008"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.025338"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.2982"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.9492"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7874"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10720"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1128"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210591"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1701"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8762"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.09000.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.09000.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:43:43Z","timestamp":1698792223000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.09000.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1365-2141.2011.09000.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.09000.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,9]]},"assertion":[{"value":"2012-01-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}